Ernexa Therapeutics (ERNA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.09, -3.69% vs the prior close of $2.17.
- Volume 24.30K shares, 0.4x its 50-day average (light).
- New SEC filings: 8-K (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
ERNA slides 3.7% to $2.09, a 52-week low. Closed at $2.09, -3.69% vs the prior close of $2.17. Day range $2.04–$2.17, opened at $2.17.
ERNA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ERNA slides 3.7% to $2.09, a 52-week low
- Closed at $2.09, -3.69% vs the prior close of $2.17. Day range $2.04–$2.17, opened at $2.17.
- Volume was 24.30K shares, 0.4x its 50-day average of 56.11K — lighter than usual.
- Price is -44.5% vs its 50-day average ($3.76) and -76.3% vs its 200-day average ($8.82).
- 52-week range $2.01–$71.50; today's close sits at 0% of that range, 97.1% below the 52-week high.
Oct 15, 2026 — ERNA rises 2.8% to $2.17
- Closed at $2.17, +2.84% vs the prior close of $2.11. Day range $2.05–$2.23, opened at $2.10.
- Volume was 6.10K shares, 0.1x its 50-day average of 57.72K — lighter than usual.
- Price is -43.0% vs its 50-day average ($3.81) and -75.8% vs its 200-day average ($8.96).
- 52-week range $2.01–$71.50; today's close sits at 0% of that range, 97.0% below the 52-week high.
- SEC filings that day: 8-K.
Oct 14, 2026 — ERNA slides 4.5% to $2.11, a 52-week low, 4 down days in a row
- Closed at $2.11, -4.52% vs the prior close of $2.21. Day range $2.01–$2.20, opened at $2.20.
- Volume was 10.20K shares, 0.2x its 50-day average of 59.59K — lighter than usual.
- Price is -45.2% vs its 50-day average ($3.85) and -76.8% vs its 200-day average ($9.09).
- 52-week range $2.01–$71.50; today's close sits at 0% of that range, 97.0% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — ERNA ends flat (+0.0%) to $2.21, 3 down days in a row
- Closed at $2.21, +0.00% vs the prior close of $2.21. Day range $2.18–$2.24, opened at $2.19.
- Volume was 8.00K shares, 0.1x its 50-day average of 60.27K — lighter than usual.
- Price is -43.2% vs its 50-day average ($3.89) and -76.1% vs its 200-day average ($9.24).
- 52-week range $2.12–$71.50; today's close sits at 0% of that range, 96.9% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — ERNA slides 7.9% to $2.21, a 52-week low
- Closed at $2.21, -7.92% vs the prior close of $2.40. Day range $2.13–$2.40, opened at $2.40.
- Volume was 30.60K shares, 0.5x its 50-day average of 60.19K — lighter than usual.
- Price is -43.6% vs its 50-day average ($3.92) and -76.4% vs its 200-day average ($9.38).
- 52-week range $2.12–$71.50; today's close sits at 0% of that range, 96.9% below the 52-week high.
Oct 9, 2026 — ERNA slides 3.6% to $2.40
- Closed at $2.40, -3.61% vs the prior close of $2.49. Day range $2.25–$2.49, opened at $2.45.
- Volume was 46.50K shares, 0.8x its 50-day average of 59.98K.
- Price is -39.1% vs its 50-day average ($3.94) and -74.8% vs its 200-day average ($9.53).
- 52-week range $2.12–$71.50; today's close sits at 0% of that range, 96.6% below the 52-week high.
Oct 8, 2026 — ERNA jumps 4.2% to $2.49 on 3.8x normal volume
- Closed at $2.49, +4.18% vs the prior close of $2.39. Day range $2.12–$2.70, opened at $2.40.
- Volume was 213.70K shares, 3.8x its 50-day average of 56.20K — unusually heavy trading.
- Price is -37.1% vs its 50-day average ($3.96) and -74.3% vs its 200-day average ($9.67).
- 52-week range $2.12–$71.50; today's close sits at 1% of that range, 96.5% below the 52-week high.
Oct 7, 2026 — ERNA jumps 6.7% to $2.39 on 15.1x normal volume
- Closed at $2.39, +6.70% vs the prior close of $2.24. Day range $2.15–$2.39, opened at $2.25.
- Volume was 662.90K shares, 15.1x its 50-day average of 43.91K — unusually heavy trading.
- Price is -40.0% vs its 50-day average ($3.98) and -75.7% vs its 200-day average ($9.83).
- 52-week range $2.15–$71.50; today's close sits at 0% of that range, 96.7% below the 52-week high.
Oct 6, 2026 — ERNA slides 17.0% to $2.24, a 52-week low on 2.0x normal volume
- Closed at $2.24, -17.04% vs the prior close of $2.70. Day range $2.20–$2.96, opened at $2.75.
- Volume was 87.30K shares, 2.0x its 50-day average of 42.77K — unusually heavy trading.
- Price is -44.1% vs its 50-day average ($4.00) and -77.5% vs its 200-day average ($9.97).
- 52-week range $2.20–$71.50; today's close sits at 0% of that range, 96.9% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — ERNA slides 8.8% to $2.70, a 52-week low, 3 down days in a row
- Closed at $2.70, -8.78% vs the prior close of $2.96. Day range $2.70–$3.06, opened at $3.04.
- Volume was 21.40K shares, 0.5x its 50-day average of 43.00K — lighter than usual.
- Price is -33.1% vs its 50-day average ($4.04) and -73.3% vs its 200-day average ($10.12).
- 52-week range $2.70–$71.50; today's close sits at 0% of that range, 96.2% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — ERNA ends flat (+0.0%) to $2.96
- Closed at $2.96, +0.00% vs the prior close of $2.96. Day range $2.90–$3.28, opened at $3.00.
- Volume was 40.70K shares, 0.9x its 50-day average of 43.71K.
- Price is -27.1% vs its 50-day average ($4.06) and -71.2% vs its 200-day average ($10.27).
- 52-week range $2.84–$71.50; today's close sits at 0% of that range, 95.9% below the 52-week high.
ERNA latest news & SEC filings
Every SEC filing by or about ERNA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 22, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$4.01M (prior year -$3.14M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$3.40 (prior year -$15.19) (loss narrowed vs Jun 30, 2025)
Jul 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Jun 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade ERNA
- Last results release: Mar 20, 2023 (8-K Item 2.02). Previous ones: Apr 15, 2022, Aug 17, 2021, Nov 13, 2020. Based on that rhythm, the next report is likely around Jun 19, 2023 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.72% (largest 17.0%). That is a volatile stock.
- Liquidity: about 69.18K shares (≈$144.59K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.09 vs a range of $2.01–$71.50 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:25 on May 4, 2026, 1:15 on Jun 12, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 0 sales; latest: Charles Cherington bought 4,000,000 shares on Feb 10, 2026.
- Latest filings: 8-K Oct 15, 2026; 8-K Sep 16, 2026; 8-K Sep 16, 2026.
- Share count: 1.63M shares outstanding (Aug 6, 2026), -78.7% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ERNA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.17 | 2.17 | 2.04 | 2.09 | 24.30K |
| Oct 15, 2026 | 2.10 | 2.23 | 2.05 | 2.17 | 6.10K |
| Oct 14, 2026 | 2.20 | 2.20 | 2.01 | 2.11 | 10.20K |
| Oct 13, 2026 | 2.19 | 2.24 | 2.18 | 2.21 | 8.00K |
| Oct 12, 2026 | 2.40 | 2.40 | 2.13 | 2.21 | 30.60K |
| Oct 9, 2026 | 2.45 | 2.49 | 2.25 | 2.40 | 46.50K |
| Oct 8, 2026 | 2.40 | 2.70 | 2.12 | 2.49 | 213.70K |
| Oct 7, 2026 | 2.25 | 2.39 | 2.15 | 2.39 | 662.90K |
| Oct 6, 2026 | 2.75 | 2.96 | 2.20 | 2.24 | 87.30K |
| Oct 5, 2026 | 3.04 | 3.06 | 2.70 | 2.70 | 21.40K |
| Oct 2, 2026 | 3.00 | 3.28 | 2.90 | 2.96 | 40.70K |
| Oct 1, 2026 | 3.13 | 3.24 | 2.84 | 2.96 | 35.70K |
| Sep 30, 2026 | 3.24 | 3.47 | 3.16 | 3.20 | 42.40K |
| Sep 29, 2026 | 3.74 | 3.74 | 3.04 | 3.16 | 61.40K |
| Sep 28, 2026 | 3.46 | 3.50 | 3.20 | 3.47 | 25.60K |
| Sep 25, 2026 | 3.73 | 3.85 | 3.40 | 3.45 | 21.10K |
| Sep 24, 2026 | 3.79 | 3.82 | 3.61 | 3.62 | 11.50K |
| Sep 23, 2026 | 3.73 | 3.79 | 3.65 | 3.65 | 6.20K |
| Sep 22, 2026 | 3.96 | 3.96 | 3.76 | 3.80 | 14.50K |
| Sep 21, 2026 | 4.01 | 4.01 | 3.75 | 3.96 | 13.50K |
About Ernexa Therapeutics
Ernexa Therapeutics (ERNA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 748592.
ERNA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| James Arthur Bristol | Director | Sep 1, 2026 |
| Peter Cicala | Director | Sep 1, 2026 |
| Sanjeev Luther | President and CEO | Sep 1, 2026 |
| David Polinsky | Director | Sep 1, 2026 |
| Elena Ratner | Director | Sep 1, 2026 |
| Robert J. Spiegel | Director | Sep 22, 2026 |
| William A. Wexler | Director | Sep 1, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Sanjeev Luther | President and CEO | Sep 1, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Feb 10, 2026 | Charles Cherington | Buy | 4,000,000 | $0.50 |
| Feb 10, 2026 | Charles Cherington | Buy | 4,000,000 | $0.50 |
| Feb 10, 2026 | Charles Cherington | Buy | 4,000,000 | $0.50 |
| Feb 10, 2026 | Charles Cherington | Buy | 4,000,000 | $0.50 |
ERNA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-14.08M | -2.24 | $-7.02M |
| Dec 31, 2024 | — | $-44.54M | -48.96 | $-15.84M |
| Dec 31, 2023 | — | $-21.67M | -4.08 | $-20.41M |
| Dec 31, 2022 | — | $-24.58M | -8.06 | $-20.98M |
| Dec 31, 2021 | — | $-122.55M | -56.61 | $-23.49M |
Latest balance sheet: total assets $6.32M, total liabilities $3.12M, cash $4.32M (as of Jun 30, 2026).
ERNA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Mar 20, 2023 | 8-K Item 2.02 (results) | — |
| Apr 15, 2022 | 8-K Item 2.02 (results) | — |
| Aug 17, 2021 | 8-K Item 2.02 (results) | — |
| Nov 13, 2020 | 8-K Item 2.02 (results) | — |
| Aug 7, 2020 | 8-K Item 2.02 (results) | — |
| May 19, 2020 | 8-K Item 2.02 (results) | — |
| Mar 17, 2020 | 8-K Item 2.02 (results) | — |
| Oct 30, 2019 | 8-K Item 2.02 (results) | — |
| Aug 9, 2019 | 8-K Item 2.02 (results) | — |
| May 13, 2019 | 8-K Item 2.02 (results) | — |
| Mar 20, 2019 | 8-K Item 2.02 (results) | — |
| Nov 7, 2018 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ERNA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.